INNOGEN-B(02591),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02591 INNOGEN-B

Trading 07-24 10:33:44

7.810

-0.230

-2.86%

High8.010	Low7.810	Vol144.80K
Open8.010	D1 Closing8.040	Amplitude2.49%
Mkt Cap3.57B	Tradable Cap3.28B	Total Shares457.00M
T/O1.14M	T/O Rate0.03%	Tradable Shares420.29M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02591","market":"HK","secType":"STK","nameCN":"INNOGEN-B","latestPrice":7.81,"timestamp":1784860327287,"preClose":8.04,"halted":0,"volume":144800,"delay":0,"changeRate":-0.0286069651741293,"floatShares":420285370,"shares":457000000,"eps":-0.9141127666248432,"marketStatus":"Trading","change":-0.23,"latestTime":"07-24 10:33:44","open":8.01,"high":8.01,"low":7.81,"amount":1137302,"amplitude":0.024876,"askPrice":7.84,"askSize":800,"bidPrice":7.81,"bidSize":34400,"shortable":3,"etf":0,"ttmEps":-0.9569256430363864,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1784865600000},"marketStatusCode":2,"adr":0,"listingDate":1755187200000,"exchange":"SEHK","adjPreClose":8.04,"openAndCloseTimeList":[[1784856600000,1784865600000],[1784869200000,1784880000000]],"volumeRatio":0.336949,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02591","defaultTab":"news","newsList":[{"id":"2651156964","title":"Guangzhou Innogen Pharmaceutical Group Co., Ltd (HKG:2591): Is Breakeven Near?","url":"https://stock-news.laohu8.com/highlight/detail?id=2651156964","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651156964?lang=en_us&edition=fundamental","pubTime":"2026-07-16 11:38","pubTimestamp":1784173082,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd ( HKG:2591 ) is possibly approaching a major achievement in its...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2591/guangzhou-innogen-pharmaceutical-group-shares/news/guangzhou-innogen-pharmaceutical-group-co-ltd-hkg2591-is-bre","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2591/guangzhou-innogen-pharmaceutical-group-shares/news/guangzhou-innogen-pharmaceutical-group-co-ltd-hkg2591-is-bre","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101364795","title":"Assessing Supply Chain Compliance Risks for a Company with a Single Commercial Product: The INNOGEN-B Patent Infringement Case","url":"https://stock-news.laohu8.com/highlight/detail?id=1101364795","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101364795?lang=en_us&edition=fundamental","pubTime":"2026-07-10 14:21","pubTimestamp":1783664460,"startTime":"0","endTime":"0","summary":"The Beijing Intellectual Property Court has recently accepted a utility model patent infringement case filed by Suzhou Jiashu Biology against Shanghai Yinno Medicine and Beijing JD Pharmacy. While JD...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123803607","title":"INNOGEN-B Shares Surge Over 17% Following NMPA Approval for Adolescent Weight Loss Trial of Esupaglutide α","url":"https://stock-news.laohu8.com/highlight/detail?id=1123803607","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123803607?lang=en_us&edition=fundamental","pubTime":"2026-06-23 09:58","pubTimestamp":1782179905,"startTime":"0","endTime":"0","summary":"Shares of INNOGEN-B (02591) are currently trading sharply higher, with gains exceeding 17%. At the time of writing, the stock is up 14.03% to HK$8.94, with a trading turnover of HK$45.71 million.The...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161","BK4588","IND","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645040877","title":"Innogen Pharmaceutical CEO addresses DIA Global Annual Meeting 2026 China Town Hall","url":"https://stock-news.laohu8.com/highlight/detail?id=2645040877","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645040877?lang=en_us&edition=fundamental","pubTime":"2026-06-22 16:40","pubTimestamp":1782117613,"startTime":"0","endTime":"0","summary":"Innogen joined the DIA Global Annual Meeting 2026 China Town Hall session in Philadelphia.CEO Qinghua Wang outlined efsubaglutide alfa’s China approval for type 2 diabetes, citing ongoing obesity Phase 2 in Australia, diabetes bridging study in Brazil.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL147jTz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645044484","title":"BUZZ-Guangzhou Innogen climbs on clinical trials approval on obesity drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2645044484","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645044484?lang=en_us&edition=fundamental","pubTime":"2026-06-22 15:36","pubTimestamp":1782113804,"startTime":"0","endTime":"0","summary":"BUZZ-Guangzhou Innogen climbs on clinical trials approval on obesity drug** Shares of Guangzhou Innogen Pharmaceutical Group 2591.HK climb 4.4% to HK$7.87, on course for the biggest one-day pct gain since May 19** Hong Kong-listed pharmaceutical products developer says it has received approval from China's National Medical Products Administration to commence Phase Ib clinical trials for its Efsubaglutide Alfa for the treatment of obesity in adolescents** Company expects to commence clinical trial in July 2026 and plans to enroll about 36 participants for the clinical trial** YTD, stock down 74.6%, Hang Seng Biotech Index .HSBIO donw 15.7%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nL1N42U07V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645497610","title":"BRIEF-Guangzhou Innogen Pharmaceutical Says On 17 June, Receives Approval To Start Phase IB Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2645497610","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645497610?lang=en_us&edition=fundamental","pubTime":"2026-06-22 14:48","pubTimestamp":1782110893,"startTime":"0","endTime":"0","summary":"BRIEF-Guangzhou Innogen Pharmaceutical Says On 17 June, Receives Approval To Start Phase IB Trial June 22  - Guangzhou Innogen Pharmaceutical Group Co Ltd 2591.HK:GUANGZHOU INNOGEN PHARMACEUTICAL GROUP CO - ON 17 JUNE, RECEIVES CHINA APPROVAL TO START PHASE IB TRIAL FOR EFSUBAGLUTIDE ALFA IN ADOLESCENT OBESITYFurther company coverage: 2591.HK ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nFWN42S06K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645049125","title":"Innogen Pharma Gets Clinical Trial Nod for Obesity Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2645049125","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645049125?lang=en_us&edition=fundamental","pubTime":"2026-06-22 14:38","pubTimestamp":1782110339,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical  obtained approval to conduct phase Ib clinical trials for Efsubaglutide Alfa from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.The drug is being tested for the treatment of obesity in adolescents.The company expects to begin the trial in July and enroll around 36 participants.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183559762","title":"INNOGEN-B Receives NMPA Clearance for Phase Ib Trial of Esupaglutide Alpha in Adolescent Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=1183559762","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183559762?lang=en_us&edition=fundamental","pubTime":"2026-06-22 12:49","pubTimestamp":1782103749,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) has announced that it received approval from China's National Medical Products Administration (NMPA) on June 17, 2026, to initiate a Phase Ib clinical trial for its drug candidate,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645704354","title":"Guangzhou Innogen Pharmaceutical Group Co - on 17 June, Receives China Approval to Start Phase Ib Trial for Efsubaglutide Alfa in Adolescent Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2645704354","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645704354?lang=en_us&edition=fundamental","pubTime":"2026-06-22 12:07","pubTimestamp":1782101278,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nFWN42S06K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185876958","title":"Innogen Pharmaceutical Sets 29 June 2026 AGM; Seeks to Scrap Supervisory Committee and Launch Share Award Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1185876958","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185876958?lang=en_us&edition=fundamental","pubTime":"2026-06-05 20:05","pubTimestamp":1780661110,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (“Innogen Pharmaceutical”), stock name INNOGEN-B, has issued a proxy circular outlining 24 resolutions to be tabled at its annual general meeting...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155251925","title":"INNOGEN-B AGM Agenda: Share Award Scheme, 20% Issue Mandate, Supervisory Committee Abolition","url":"https://stock-news.laohu8.com/highlight/detail?id=1155251925","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155251925?lang=en_us&edition=fundamental","pubTime":"2026-06-05 19:26","pubTimestamp":1780658769,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (“INNOGEN-B”) has published a circular for its Annual General Meeting (AGM) scheduled on 29 June 2026 in Shanghai, detailing 17 resolutions for...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179509312","title":"INNOGEN-B Shares Surge Over 9% as Its Proprietary Drug Features at Major Diabetes Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=1179509312","media":"Stock News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179509312?lang=en_us&edition=fundamental","pubTime":"2026-06-05 11:12","pubTimestamp":1780629145,"startTime":"0","endTime":"0","summary":"Shares of INNOGEN-B (02591) surged more than 9% during the trading session. At the time of writing, the stock was up 3.21% to HK$10.28, with a turnover of HK$34.87 million. The catalyst for the move...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","VXUS","BK1161","BK4588","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134785093","title":"INNOGEN-B’s May 2026 Monthly Return Shows Stable Share Structure and Compliance With Public Float Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=1134785093","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134785093?lang=en_us&edition=fundamental","pubTime":"2026-06-03 17:25","pubTimestamp":1780478754,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (INNOGEN-B) filed its Monthly Return for the period ended 31 May 2026, confirming that no changes occurred in either authorised or issued share...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162227797","title":"INNOGEN-B Shares Surge Over 6% Ahead of Key Clinical Data Presentation at ADA 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1162227797","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162227797?lang=en_us&edition=fundamental","pubTime":"2026-06-03 11:08","pubTimestamp":1780456101,"startTime":"0","endTime":"0","summary":"Shares of INNOGEN-B (02591) have risen more than 6%. At the time of writing, the stock is up 5.79% to HK$10.62, with a turnover of HK$90.33 million.The company has announced that it will present data...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","02591","BK1161","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116975222","title":"Movement Alert｜Yinnuo Pharma-B Rises 10.68% in Regular Trading, Share Award Plan and Commercialization Acceleration Drive Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=1116975222","media":"Market Focus","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116975222?lang=en_us&edition=fundamental","pubTime":"2026-06-03 10:38","pubTimestamp":1780454339,"startTime":"0","endTime":"0","summary":"On June 3, Yinnuo Pharma-B rose 10.68% in regular trading, trading at 11.37 HKD/share, with trading volume of approximately 29.62 million HKD, significantly outperforming the broader Biotechnology...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132169066","title":"INNOGEN-B Proposes Adoption of Share Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1132169066","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132169066?lang=en_us&edition=fundamental","pubTime":"2026-06-01 22:40","pubTimestamp":1780324820,"startTime":"0","endTime":"0","summary":"INNOGEN-B (HKEX: 02591) has announced that its board of directors has proposed the adoption of a share reward plan.In accordance with the provisions of the company's articles of association, a...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","301122","BK0251","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640505849","title":"Guangzhou Innogen proposes 10-year share award scheme with 10% issuance cap","url":"https://stock-news.laohu8.com/highlight/detail?id=2640505849","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640505849?lang=en_us&edition=fundamental","pubTime":"2026-06-01 22:24","pubTimestamp":1780323892,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group proposed a 10-year Share Award Scheme, set to take effect on June 29, 2026, subject to shareholder approval.Scheme mandate caps awards at 10% of issued shares, excluding treasury shares; service provider awards capped at 1% as a sublimit.Based on 456,819,349 shares outstanding, the mandate limit equals 45,681,934 shares; the service provider sublimit equals 4,568,193 shares.Award shares may be satisfied via new H shares issued to a trustee, H shares bought in the market, or transfers of treasury shares.Vesting set by the board per grant; standard minimum vesting is 12 months, with limited exceptions for employee participants.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmac","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDLDJ9T3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640528579","title":"Guangzhou Innogen Pharmaceutical proposes re-election of entire board slate for three-year term","url":"https://stock-news.laohu8.com/highlight/detail?id=2640528579","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640528579?lang=en_us&edition=fundamental","pubTime":"2026-06-01 21:16","pubTimestamp":1780319760,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group set a shareholder vote to re-elect its entire board for a new three-year term.Proposed executive directors include founder-chairman and general manager Wang Qinghua, a metabolic-disease researcher with academic posts at the University of Toronto.Finance chief and board secretary Jiang Fan, a former strategy consultant and pharma investment-and-financing executive, is also up for re-election as an executive director.The board also proposed abolishing the supervisory committee, shifting oversight to a revised governance structure.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDLWqCX4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639620422","title":"Innogen says Phase IIb trial shows efsubaglutide alfa cuts weight up to 10.58% in adults with obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2639620422","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639620422?lang=en_us&edition=fundamental","pubTime":"2026-05-29 21:09","pubTimestamp":1780060155,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group flagged Phase IIb ENLIGHT results for obesity drug efsubaglutide alfa for presentation at the ADA meeting on June 8, 2026.The trial met its primary endpoint, with treated participants showing meaningful weight loss versus placebo and continued reduction through the dosing period.Innogen also reported improvements in body composition and metabolic markers, with weight loss driven mainly by fat rather than muscle.Safety looked manageable, with no hypoglycemia reported and mostly mild-to-moderate gastrointestinal side effects.The data set underpins plans to advance efsubaglutide alfa into Phase III development in obesity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL5SQw8z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160792896","title":"Stock Track | INNOGEN-B Plummets 6.52% Intraday as Cornerstone Investor Lock-ups Expire","url":"https://stock-news.laohu8.com/highlight/detail?id=1160792896","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160792896?lang=en_us&edition=fundamental","pubTime":"2026-05-15 12:12","pubTimestamp":1778818329,"startTime":"0","endTime":"0","summary":"INNOGEN-B's stock price plummeted 6.52% during Friday's intraday trading session, with the decline occurring around mid-morning.The sharp drop came as cornerstone investor lock-ups expired, allowing...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innogenpharm.com","stockEarnings":[{"period":"1week","weight":-0.0371},{"period":"1month","weight":0.0101},{"period":"3month","weight":-0.5228},{"period":"6month","weight":-0.7457},{"period":"1year","weight":-0.5696},{"period":"ytd","weight":-0.7376}],"compareEarnings":[{"period":"1week","weight":0.0081},{"period":"1month","weight":0.0803},{"period":"3month","weight":-0.0295},{"period":"6month","weight":-0.0575},{"period":"1year","weight":-0.0128},{"period":"ytd","weight":-0.0164}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Guangzhou Innogen Pharmaceutical Group Co Ltd is a China-based investment holding company principally engaged in the research, development and commercialisation of pharmaceutical products. The Company is primarily engaged in the commercialization of innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. The Company is dedicated to developing therapies for diabetes and other metabolic diseases. The Company’s core product, Efsubaglutide Alfa (brand name: Diabegone), is used for the treatment of type 2 diabetes (T2D). The Company’s primary pipeline drug candidates include YN014, YN401, YN209, YN203, and YN202. The Company principally conducts its businesses in the domestic market.","exchange":"SEHK","name":"INNOGEN-B","nameEN":"INNOGEN-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"INNOGEN-B(02591),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest INNOGEN-B(02591) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"INNOGEN-B,02591,INNOGEN-B股票,INNOGEN-B股票老虎,INNOGEN-B股票老虎国际,INNOGEN-B行情,INNOGEN-B股票行情,INNOGEN-B股价,INNOGEN-B股市,INNOGEN-B股票价格,INNOGEN-B股票交易,INNOGEN-B股票购买,INNOGEN-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"INNOGEN-B(02591),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest INNOGEN-B(02591) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}